The evaluation of molecular targets in gastric cancer has demonstrated the predictive role of HER2 amplification for trastuzumab treatment in metastatic gastric cancer. Besides HER2, other molecular targets are under evaluation in metastatic gastric tumors. However, very little is known about their role in resected tumors. We evaluated the expression of HER2, EGFR, MET, AKT1 and phospho-mTOR in resected stage II-III adenocarcinomas
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of ...
Gastric and esophageal adenocarcinomas are major global cancer burdens. These cancer forms are chara...
Members of the human epidermal growth factor receptor (HER) family have been of considerable interes...
The evaluation of molecular targets in gastric cancer has demonstrated the predictive role of HER2 a...
Background: Trastuzumab is effective for the treatment of advanced gastric cancers with HER2 amplifi...
Gastric cancer is a major cause of cancer-related deaths in both men and women. The epidermal growth...
[Background] A recent randomized controlled trial (Trastuzumab for Gastric Cancer [ToGA] study) esta...
HER2 expression in gastric cancer (GC) has received attention as a potential target for therapy with...
Most gastric adenocarcinomas arise as a longterm complication of Helicobacter pylori infection of th...
Background: Gastric cancer is one of the commonest malignant tumor worldwide. Its treatment remains ...
Background Met and HER-2 are proto-oncogenes encoding receptor tyrosine kinase c-Met and HER-2, resp...
Purpose: Identification of critical genes which play pivotal roles in controlling tumor growth and s...
Surgery is the only curative therapy for gastric cancer. In the metastatic setting the objective of ...
The assessment of human epidermal growth factor receptor 2 (HER2) gene amplification is essential in...
In this study, we investigated the rate of human epidermal growth factor receptor 2 (HER2) overexpre...
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of ...
Gastric and esophageal adenocarcinomas are major global cancer burdens. These cancer forms are chara...
Members of the human epidermal growth factor receptor (HER) family have been of considerable interes...
The evaluation of molecular targets in gastric cancer has demonstrated the predictive role of HER2 a...
Background: Trastuzumab is effective for the treatment of advanced gastric cancers with HER2 amplifi...
Gastric cancer is a major cause of cancer-related deaths in both men and women. The epidermal growth...
[Background] A recent randomized controlled trial (Trastuzumab for Gastric Cancer [ToGA] study) esta...
HER2 expression in gastric cancer (GC) has received attention as a potential target for therapy with...
Most gastric adenocarcinomas arise as a longterm complication of Helicobacter pylori infection of th...
Background: Gastric cancer is one of the commonest malignant tumor worldwide. Its treatment remains ...
Background Met and HER-2 are proto-oncogenes encoding receptor tyrosine kinase c-Met and HER-2, resp...
Purpose: Identification of critical genes which play pivotal roles in controlling tumor growth and s...
Surgery is the only curative therapy for gastric cancer. In the metastatic setting the objective of ...
The assessment of human epidermal growth factor receptor 2 (HER2) gene amplification is essential in...
In this study, we investigated the rate of human epidermal growth factor receptor 2 (HER2) overexpre...
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of ...
Gastric and esophageal adenocarcinomas are major global cancer burdens. These cancer forms are chara...
Members of the human epidermal growth factor receptor (HER) family have been of considerable interes...